[G17-09] Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V

Last updated 02.01.2018

Project no.:

Commission awarded on 28.09.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Health Economics

Application field:
Skin and hair


In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the avelumab report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier. After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.

Federal Joint Committee (G-BA)

2018-03-16 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form